NPM1 and acute myeloid leukemia: Despite various clinical trials and research of new agents targeting NPM1-mutants, about 50% of patients either relapse or unfortunately die due to the progression of the disease, and this is often the case in patients who are unable to withstand the clinically aggressive nature of AML, nor the harshness of intensive chemotherapy required for disease remission.